BI, Lilly expand Jardiance programme in heart failure
Boehringer Ingelheim and Eli Lilly are expanding their clinical trial programme for Jardiance in chronic heart failure (CHF) with two new Phase III studies.
Read More
Tag: CHF
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
